Document is current
Any future updates will be listed below
-
Authors
McIntyre, Roger S.
Llorca, Pierre-Michel
Aronin, Lauren C.
Yu, Jun
Nguyen, Huy-Binh
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02670538 at ClinicalTrials.govnct02670551 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials
https://doi.org/10.1007/s12325-024-03009-2
nct01396447 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials
https://doi.org/10.1007/s12325-024-03009-2
Documents that mention this clinical trial
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials
https://doi.org/10.1007/s12325-024-03009-2
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 25 September 2024
First Online: 9 November 2024
Declarations
:
: Roger S. McIntyre has received research grant support from the Canadian Institute of Health Research (CIHR), Global Alliance for Chronic Diseases (GACD), Milken Institute, and the National Natural Science Foundation of China (NSFC); has received speaker/consultation fees from AbbVie, Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Janssen, Kris, Intra-Cellular, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, NewBridge Pharmaceuticals, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris; is a CEO of Braxia Scientific Corp. Roger S. McIntyre is an Editorial Board member of Advances in Therapy. Roger S. McIntyre was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Pierre-Michel Llorca has participated in advisory boards for Eisai, Ethypharm, Janssen, Lundbeck, MSD, Neuraxpharm, Novartis, Otsuka, Roche, and Rovi; has received speaker’s honoraria and consultation fees from AbbVie, Eisai, Ethypharm, Janssen, Lundbeck, MSD, Neuraxpharm, Novartis, Otsuka, Roche, and Rovi; is member of the Executive Committee of Fondation FondaMental; and has been involved in developing National Care Guidelines for the French Society for Biological Psychiatry and Neuropsychopharmacology on the treatment of major depression. Lauren C. Aronin, Jun Yu, and Huy-Binh Nguyen are employees of AbbVie and may hold stock.
: No prospective data were collected during this post hoc analysis and therefore ethical approval was not required. During the original trials, all study protocols complied with the Declaration of Helsinki and Good Clinical Practice guidelines and were approved by an institutional review board (US centers) or an ethics committee/government agency (non-US centers). Written informed consent was obtained from all patients included in the trials.
